New Drug Update 2010-2011 Faculty Disclaimer - CME Conferences
New Drug Update 2010-2011 Faculty Disclaimer - CME Conferences
New Drug Update 2010-2011 Faculty Disclaimer - CME Conferences
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
2 nd Annual Essentials in Primary Care<br />
Fall Conference<br />
Friday, November 11, <strong>2011</strong><br />
Buprenorphine Transdermal System - Butrans<br />
Table 2. Adverse Events of Buprenorphine vs Placebo in Patients Being Treated for Chronic Pain<br />
With a Dose That Was Titrated to Effect<br />
Adverse Events<br />
Buprenorphine<br />
(n = 392)<br />
Placebo<br />
(n = 261)<br />
Nausea 23% 8%<br />
Dizziness 16% 8%<br />
Headache 16% 11%<br />
Application-site pruritus 15% 12%<br />
Constipation 14% 5%<br />
Somnolence 14% 5%<br />
Vomiting 11% 2%<br />
Peripheral edema 7% 3%<br />
Application-site erythema 7% 2%<br />
Dry mouth 7% 2%<br />
Application-site rash 6% 6%<br />
Fatigue 5% 1%<br />
Fall 4% 2%<br />
Hyperhidrosis 4% 1%<br />
Pruritus 4% 1%<br />
Buprenorphine Transdermal System - Butrans<br />
DOSING:<br />
• The transdermal system (patch) is applied every 7 days to the upper<br />
outer arm, upper chest, upper back, or side of the chest on either<br />
side of the body.<br />
– Application should be rotated among these 8 sites and a<br />
minimum of 3 weeks should elapse before applying a patch to<br />
the same site.<br />
– The patch should be applied to a hairless or nearly hairless skin<br />
site. The hair at the site should be clipped, not shaven.<br />
– If there are adhesion problems with the patch, the edges may be<br />
taped down with first aid tape or covered with see-through<br />
adhesive dressing (eg, Bioclusive, Tegaderm).<br />
– If the patch falls off during the 7-day dosing interval, a new patch<br />
should be applied at a different skin site.<br />
– The buprenorphine transdermal system should not be cut.<br />
Wayne Weart<br />
<strong>New</strong> <strong>Drug</strong> <strong>Update</strong> Part I